These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 27689845)

  • 1. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
    Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
    Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
    Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Klevebro F; Lindblad M; Ye W; Lundell L; Nilsson M
    Br J Surg; 2014 Mar; 101(4):321-38. PubMed ID: 24493117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.
    Lagarde SM; Navidi M; Gisbertz SS; van Laarhoven HW; Sumpter K; Meijer SL; Disep B; Immanuel A; Griffin SM; van Berge Henegouwen MI
    Br J Surg; 2016 Nov; 103(12):1658-1664. PubMed ID: 27696382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction.
    Faron M; Cheugoua-Zanetsie AM; Thirion P; Nankivell M; Winter K; Cunningham D; Van der Gaast A; Law S; Langley R; de Vathaire F; Valmasoni M; Mauer M; Roth J; Gebski V; Burmeister BH; Paoletti X; van Sandick J; Fu J; Ducreux M; Blanchard P; Tierney J; Pignon JP; Michiels S;
    Eur J Cancer; 2021 Nov; 157():278-290. PubMed ID: 34555647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: A nationwide study.
    van der Werf LR; Dikken JL; van der Willik EM; van Berge Henegouwen MI; Nieuwenhuijzen GAP; Wijnhoven BPL;
    Eur J Cancer; 2018 Mar; 91():76-85. PubMed ID: 29353163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
    Markar SR; Gronnier C; Pasquer A; Duhamel A; Beal H; Théreaux J; Gagnière J; Lebreton G; Brigand C; Meunier B; Collet D; Mariette C;
    Eur J Cancer; 2016 Mar; 56():59-68. PubMed ID: 26808298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
    Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
    Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
    Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
    Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographical differences in cancer treatment and survival for patients with oesophageal and gastro-oesophageal junctional cancers.
    Jestin Hannan C; Linder G; Kung CH; Johansson J; Lindblad M; Hedberg J
    Br J Surg; 2020 Oct; 107(11):1500-1509. PubMed ID: 32484241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis.
    Hölscher AH; Bollschweiler E; Bogoevski D; Schmidt H; Semrau R; Izbicki JR
    Eur J Cancer; 2014 Nov; 50(17):2950-7. PubMed ID: 25307749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma.
    Morgan MA; Lewis WG; Casbard A; Roberts SA; Adams R; Clark GW; Havard TJ; Crosby TD
    Br J Surg; 2009 Nov; 96(11):1300-7. PubMed ID: 19847875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy.
    Karran A; Blake P; Chan D; Reid TD; Davies IL; Kelly M; Roberts SA; Crosby T; Lewis WG
    Br J Surg; 2014 Apr; 101(5):502-10. PubMed ID: 24615406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials.
    Liu B; Bo Y; Wang K; Liu Y; Tang X; Zhao Y; Zhao E; Yuan L
    Oncotarget; 2017 Mar; 8(12):20410-20417. PubMed ID: 28099899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
    Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
    Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
    Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
    Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
    Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer.
    Kranzfelder M; Schuster T; Geinitz H; Friess H; Büchler P
    Br J Surg; 2011 Jun; 98(6):768-83. PubMed ID: 21462364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.